Demsky joined the University of Michigan Rogel Cancer Center communications team in 2019. Prior to that he served as director of communications for the University of Michigan's Life Sciences Institute and science editor for Medicine at Michigan Magazine. Contact: idemsky@med.umich.edu
A new understanding of intracellular pathways activated as T cells start to mount an immune response offers clues against graft-versus-host disease, a serious complication of bone marrow transplantation.
A combination approach, which included metabolic reprogramming and immunotherapy, led to complete tumor regression in 60% of study mice.
Throughout the pandemic, researchers have continued to push the boundaries of cancer prevention, diagnosis and treatment.
Increasingly, scientists like those at the Rogel Cancer Center are using 3-D cell cultures to more closely model cancer cells in the body.
The analysis highlights the diversity of immune response in pancreatic cancer, and points toward the need for treatments tailored to individual patients.
The U-M-led development and validation of a staging system for non-metastatic prostate cancer could help doctors and patients assess treatment options, as well as improve clinical trials.
